comparemela.com

Latest Breaking News On - Cannabis research licence - Page 1 : comparemela.com

Australia s Cann Group Scores New CEO

A new CEO with decades of pharmaceutical industry experience is taking the helm at Australian medical cannabis firm Cann Group (ASX: CAN).

Asia pacificCann milduraPeter koetsierAustralian government office of drug controlSativite pty ltdCannabis research licenceCann groupChief executive officerTuesday peter koetsierPeter crockCann group chairAllan mccallumSouthern facilityAustralian governmentDrug controlMedicinal cannabis cultivation

City View Green Holdings Inc : City View Receives Health Canada Research License for Product Tasting of Cannabis

Toronto, Ontario (Newsfile Corp. - April 21, 2022) - City View Green Holdings Inc. (CSE: CVGR) (OTCQB: CVGRF) ("City View" or the "Company"), a leading consumer packaged goods company focused on the

Steve naraineBudd huttCannabis research licence under health canadaNewsfile corpCity view green holdings incNeither the canadian securities exchangeHealth canadaBudd hutt incView green holdingsCannabis research licenceCannabis actCity viewCanadian securities exchange

CANNTAB ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT, WARRANT EXPIRY EXTENSION AND CORPORATE UPDATE

/PRNewswire/ Canntab Therapeutics Limited ("Canntab" or the "Company") (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1), the leading innovator in cannabinoid and terpene.

Richard goldsteinBarry polisukFirst republic capital corporationCannabis research licenceFrankfurt stock exchangePrnewswire canntab therapeutics limitedCompany onCompany debenturesNeither the canadian securities exchangeHealth canadaCanadian securities exchangeTherapeutics limitedConversion priceClosing dateConvertible debentureMultilateral instrument

CANNTAB ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT, WARRANT EXPIRY EXTENSION AND CORPORATE UPDATE

TORONTO, Feb. 1, 2022 /PRNewswire/ Canntab Therapeutics Limited , the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to. | February 2, 2022

United statesRichard goldsteinBarry polisukFirst republic capital corporationCanntab therapeuticsCannabis research licenceFrankfurt stock exchangeCanntab therapeutics limitedUs newswire servicesCompany debenturesNeither the canadian securities exchangeHealth canadaCanadian securities exchangeTherapeutics limitedConversion priceClosing date

CANNTAB ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT, WARRANT EXPIRY EXTENSION AND CORPORATE UPDATE

/PRNewswire/ Canntab Therapeutics Limited ("Canntab" or the "Company") (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1), the leading innovator in cannabinoid and terpene.

Richard goldsteinBarry polisukFirst republic capital corporationCannabis research licenceFrankfurt stock exchangePrnewswire canntab therapeutics limitedCompany onCompany debenturesNeither the canadian securities exchangeHealth canadaCanadian securities exchangeTherapeutics limitedConversion priceClosing dateConvertible debentureMultilateral instrument

vimarsana © 2020. All Rights Reserved.